Toward optimal moxifloxacin dosing in tuberculous meningitis: A translational physiologically based pharmacokinetic modeling approach
These results suggest that higher doses might be needed to ensure PK target attainment in TBM, regardless of whether moxifloxacin is combined with rifampicin. The safety of regimens exceeding 800 mg must be rigorously established in clinical trials.
Authors
- Theis Mariager (ORCID: https://orcid.org/0000-0001-8135-561X)
- L Lange
- Rob Christiaan van Wijk (ORCID: https://orcid.org/0000-0001-7247-1360)
- Martijn L. Manson (ORCID: https://orcid.org/0000-0002-5508-8615)
- Jacob Bodilsen
- Roland Nau
- Katie Lynch
- Ming Sun
- Tingjie Guo
Institutions
- Aalborg University Hospital (DK)
- Centre for Human Drug Research (NL)
- Evangelisches Krankenhaus Göttingen-Weende (DE)
- Aalborg University (DK)
Publication Details
- Journal
- European Journal of Pharmaceutical Sciences
- Published
- 2026-02-18
- DOI
- https://doi.org/10.1016/j.ejps.2026.107478
- Primary Topic
- Infectious Diseases and Tuberculosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00